Newcross Healthcare Solutions’ Post

On World AIDS Day, we honour the resilience of those affected by HIV/AIDS. Let's stand together, fight stigma, and work towards a world where no one has to suffer from this preventable disease. #WorldAIDSDay #EndAIDS #HIVAwareness #WAD2023 #KnowYourStatus #AIDSAwareness #clinicalresearch #pharmaceuticals #pharma #clinical #clinicaltrials #JSTL #Jeevanscientific #Jeevanscientifictechnologylimited

GSK CEO Emma Walmsley's total pay rises 51% to nearly 13 mln pounds in 2023 Walmsley, chief executive since 2017, has been pivotal in sharpening GSK's focus on vaccines and infectious diseases, and shifting its HIV focus to long-acting treatment and prevention therapies, amid a series of upcoming patent expiries, litigations and declining revenue from current bestsellers. #GSKCEO | #EmmaWalmsley | #infecticiousdiseases | #upcomingpatentexpiries | #Healthnews Read more:

Thoughts on this? >> BridgeBio's $250M offering; ViiV's PhI data for ultra-long-acting HIV treatment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

Thoughts on this? >> GSK says Dovato was as effective as Biktarvy in head-to-head HIV trial — but patients gained less weight >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #healthcare #biotech #pharmaceutical

Let’s acknowledge the tireless hard work of all the scientists and health professionals to find a safe and effective vaccine to prevent HIV infection. . . . #unimarckpharma #unimarck #youthhivawareness #endstigma #unimarckcares #hivaidsvaccine #hivaids #pharmaceuticalindustry #pharmacompany #pharmaindustry #pharmaceuticals #pharma #pharmacompanies #manufacturers #thirdpartyservices #thirdpartymanufacturing #thirdpartymanufacturers #contractmanufacturer #manufacturingunit

Thoughts on this? >> BridgeBio's $250M offering; ViiV's PhI data for ultra-long-acting HIV treatment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #biotech #pharma

A study in CID examines the comparative diagnostic performance of polymerase chain reaction (PCR) for the diagnosis of Pneumocystis pneumonia (PCP) on different respiratory tract samples, in both HIV and non-HIV populations. https://lnkd.in/e_yhx8n8

📃Scientific paper: Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir Abstract: The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment options for people with multi-drug resistant HIV remain limited. Medication resistance, undesirable effects, prior tolerance, and previous interlacement incapacity to deliver new drug classes all lead to the requirement for new medication classes and drug combination therapy. Fostemsavir (FTR) is a new CD-4 attachment inhibitor medicine that was recently authorized by the United States FDA to treat HIV-1. In individuals with multidrug-resistant (MDR) HIV-1, FTR is well tolerated and virologically active. According to recent investigations, drug combination therapy can positively affect MDR-HIV. The mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of FTR has been highlighted in this review. Continued on ES/IODE ➡️ https://etcse.fr/yFk7n ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

ASCP Daily Diagnosis 12/15 CST Mpox vaccination with a two-shot, low-dose intradermal approach produced similar antibody titers levels compared with the standard subcutaneous dosing regimen. It was a good surprise to find out that people with well-controlled HIV (with CD4+ cell counts above 200) are able to develop similar antibodies as people without HIV. This is an important message as this patient population has been more vulnerable to mpox. This study demonstrated the importance of receiving the full two-dose schedule of the mpox vaccine, especially in people with HIV -- which is a population that has been understudied in the context of this vaccine and clinically the most vulnerable population in terms of having higher mortality and severity of the disease. https://lnkd.in/gMKahCTr

Thoughts on this? >> GSK says Dovato was as effective as Biktarvy in head-to-head HIV trial — but patients gained less weight >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech